Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events
13.2.2025 10:00:00 CET | Business Wire | Press release
Day Of The Devs Powered By Xsolla Will Celebrate Creativity And Bring Opportunities Together For Game Developers Of All Genres, Backgrounds, And Locations
Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/
(Graphic: Xsolla)
“This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and creativity and create a channel to bring opportunities together for developers, and we are proud to be a part of this initiative.”
Day of the Devs, powered by Xsolla, will include incredible events and opportunities for video game developers to showcase their new games and connect with industry leaders to help them build their gaming businesses. Kicking off 2025, Day of the Devs: San Francisco Edition will take place on Sunday, March 16, 2025, at The Midway in San Francisco, bringing thousands of indie fans and developers together to play incredible hand-picked titles. More details on the event can be found on the Eventbrite page here.
Continuing the celebration, Day of the Devs: GDC Edition will feature a selection of titles from the San Francisco Edition at the Moscone Center during the Game Developers Conference (GDC) 2025, running from March 17 to 21 on the 3rd floor of Moscone West. Attendees can explore these unreleased games during regular hours, while the public, 18 and older, can experience them during GDC Nights on Monday and Thursday evenings from 6:30 PM to 10:00 PM PT. Xsolla will also be hosting a lounge on the first floor of Moscone West to support the community and provide an area for developers to collaborate with the Xsolla team.
Day of the Devs, a non-profit organization, has celebrated video games' creativity, diversity, and magic for over 13 years. It has hosted thousands of attendees at physical events, reached millions through virtual showcases, and provided a platform for hundreds of games and developers.
“This event embodies the spirit of creativity and community that defines indie games,” said Greg Rice, Head Curator at Day of the Devs. “Thanks to partners like Xsolla, we can continue to keep these events free and accessible, allowing thousands to connect with the magic of games and the talent behind them.”
Through this sponsorship, Xsolla will engage with hundreds of game developers to support their initiatives and bring opportunities together to solve inherent questions and challenges facing their funding, distribution, and monetization efforts. This flagship sponsorship reinforces Xsolla’s commitment to supporting game developers to provide the same opportunities and connections to any game - regardless of size, location, genre, or platform. For more information, please visit: xsolla.blog/dotdgdc
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
About Day of the Devs
Day of the Devs is a non-profit with the mission to celebrate the creativity, diversity and magic of video games. Day of the Devs gives a voice to emerging or underrepresented talent with platforms that connect players with developers, and their games. Day of the Devs takes on the form of virtual and physical events – all completely free, with no costs to either developers or attendees. Over the last 13 years, Day of the Devs has shined a spotlight on many hundreds of games, hosted tens of thousands of people at in-person events, and reached out to millions of viewers through virtual showcases.
For more information, visit dayofthedevs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213515388/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom